At Wintermute Biomedical, our sole focus is to develop innovative solutions where current medicines are failing.
We are a global biopharmaceutical company, headquartered in Australia. Founded in Missoula, Montana in 2012, we have discovered next generation anti-pathogenic compounds, which we think will have a significant impact on the lives of many patients across the globe. We work tirelessly to develop state-of-the-art healthcare products for those who need it most.
Wintermute Biomedical is driven by an experienced team of healthcare innovators, infectious disease experts and entrepreneurs.
Brett has over 20 years of pharmaceutical industry experience with significant exposure across the medicine discovery, development and commercialisation lifecycle. Brett has led worldwide licensing, acquisition and venture capital backed transactions.
Tom is a Wintermute co-founder and inventor, with over 20 years experience in scientific research. He specializes in neuroscience and medical microbiology, with a particular focus on multidrug-resistant bacteria.
Tony has been Chief Executive of the Cooperative Research Centres Association for 10 years. He is a Fellow of both the Australian Academy of Technology and Engineering and the Australian Institute of Company Directors.
Elise has diverse operations and organisational management experience across several leadership roles. A natural entrepreneur, she has devoted her career to becoming a specialised generalist.
Paul is an engineer and investor with a track-record of pioneering and commercializing innovative technologies within the energy and healthcare sectors. With a unique ability to identify and nurture start-up companies, Paul joined Wintermute as the founding investor in 2012.
Margaret is a highly regarded executive leader and influential strategy and policy analyst with experience in evidence-based policy development and advice to government. She has a reputation for high level innovative and strategic thinking and planning across the public and NFP sectors.
Matt is the Managing Director of Australian Healthcare Solutions, a niche consultancy that provides seamless services to clients throughout the medtech lifecycle.
Alyce obtained her PhD from the La Trobe Institute for Molecular Science, La Trobe University. She specialises in cancer immunology, molecular biology and cell biology.
Wintermute Biomedical is surrounded by world leading experts in microbiology, antimicrobial resistance, infectious disease and medicine.
Stephen is an esteemed leader in virology, and has held multiple leadership positions at the Victorian Infectious Diseases Reference Laboratory (VIDRL) since 1989 and the World Health Organisation (WHO) Regional Reference Laboratory for Hepatitis B. His achievements in hepatitis research has underpinned several commercialisation activities.
Mark is the Head of the Department of Biochemistry and Genetics at La Trobe University. His current research interests include inflammation and the tumour micro environment, as well as the mechanism of action and therapeutic application of host defence peptides. He has published over 110 peer-reviewed papers and 8 patents.
Joe is a clinician scientist with an international reputation in viral infections. He is an infectious diseases physician at the Royal Melbourne Hospital and Alfred Hospital. With a strong research background in clinical virology, Joe has conducted over 50 clinical trials and has published over 100 articles in peer reviewed journals.
As a cancer biologist, Nik has held many national leadership positions in directing research, enhancing clinical trial activity in Australia, establishing national guidelines and infrastructure, and advising regulatory bodies, such as the TGA. Nik is currently the inaugural Group Director of Research for Epworth HealthCare, and Adjunct Professor at the Eastern Clinical School of Monash University, among many other roles.
Steven is an infectious diseases clinician researcher based at the Royal Melbourne Hospital and the Doherty Institute. His key achievements include the discovery and naming of two new species of Staphylococcus, and leading international-recognised clinical trials in infectious diseases. He is passionate about applying cutting edge science to improve the treatment of bacterial infections.
